{"prompt": "['GAP4 Clinical Study Protocol', 'INTense Exercise foR surVivAL among men with Metastatic Castrate-Resistant', 'Prostate Cancer (INTERVAL - MCRPC): A Multicentre, Randomised, Controlled,', 'Phase III Study', 'Protocol Number:', 'Investigational Product:', 'High intensity aerobic and resistance training', 'Funder:', 'Movember', 'Status:', 'Final Protocol', 'Date:', '19 April 2018', 'Prepared by: GAP4 Management Team', 'Approved by: GAP4 Steering Committee', 'Document No.: v4.0', 'GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and', 'applicable regulatory requirements.', 'The confidential information in the following document is provided to you as an investigator,', 'potential investigator, or consultant, for review by you, your staff, and appropriate ethical', 'review committee. By accepting this document, you agree that the information contained herein', 'will not be disclosed to others without written authority from Movember, except to the extent', 'necessary to obtain approval of this protocol by an ethical review committee.', 'PROTOCOL AGREEMENT', 'I confirm that I have read this protocol. I will comply with the protocol and the principles of', 'Good Clinical Practice (GCP), as described in the United States Code of Federal Regulation', '(CFR) 21 Parts 11, 50, 54, 56, and 312 and the appropriate International Conference on', 'Harmonisation guidance documents.', 'Investigator Signature', 'Date', 'Print Name and Title', 'Site Name', 'INTERVAL Protocol Version 4.0, 19 April 2018', '1']['PROTOCOL SYNOPSIS', 'Title', 'Intense exercise for survival among men with metastatic', 'castrate-resistant prostate cancer (INTERVAL - MCRPC): A', 'Multicentre, Randomised, Controlled Phase III Study', 'Funder', 'Movember', 'Phase', 'III', 'Study Design', 'Randomised Controlled Trial', 'Primary Objective', 'To determine if high intensity aerobic and resistance training (Supervised', 'Exercise) plus psychosocial support increases overall survival compared', 'to psychosocial support alone (Self-directed Exercise) in patients with', 'metastatic castrate-resistant prostate cancer.', 'Secondary Objectives', 'To compare progression free survival between the Supervised', 'Exercise (intervention) and Self-directed Exercise (control) groups.', 'To compare time to first occurrence of a symptomatic skeletal-related', 'event between the intervention and control groups.', 'To compare time to progression of pain, degree of pain, and opiate', 'use between the intervention and control groups.', 'To compare change in biomarkers of inflammation, energy', 'metabolism, and androgen metabolism over time between the', 'intervention and control groups.', 'To determine whether biomarkers of inflammation, energy', 'metabolism, and androgen metabolism are associated with overall', 'survival among men with mCRPC, and explore the extent to which', 'these biomarkers mediate the hypothesized association between', 'high-intensity aerobic and resistance exercise and survival.', 'To compare physical and emotional quality of life between the', 'intervention and control groups.', 'Number of Patients', '866', 'INTERVAL Protocol Version 4.0, 19 April 2018', '2']['Enrolment Criteria', 'Patients must be mCRPC. This is defined as adenocarcinoma of', 'the prostate with systemic metastatic disease despite castrate', 'levels of testosterone (<50 ng/dL) due to orchiectomy or LHRH', 'agonist.', 'Patients must have one or more of the following to be', 'considered mCRPC', 'Metastatic Disease Progression: >20% increase in', 'the sum of diameters of measurable lesions from the', 'time of maximal regression or appearance of one or', 'more new lesions.', 'Bone Scan Progression: Appearance of one or more', 'new lesions on bone scan attributable to prostate', 'cancer.', 'PSA Progression: PSA >2 ng/ml that has risen', 'serially on at least two occasions, each at least one', 'week apart (PSA1 < PSA2 < PSA3).', 'Castrate levels of testosterone must be maintained while on study.', 'Be on androgen deprivation therapy (ADT) with a GnRH', 'agonist/antagonist or prior bilateral orchiectomy. All patients will be', 'required to be on ADT during the study period or have had a prior', 'bilateral orchiectomy. Men with small cell neuroendocrine tumours', 'or features of small cell disease are not eligible.', 'At enrolment, patients must fit into one of the following 5 categories:', '1. Treatment na\u00efve for mCRPC (have not yet started approved', 'therapies for CRPC ie: Abiraterone/Enzalutamide/', 'Apalutamide/Docetaxel less than 4 weeks on approved therapies is', 'still considered to be treatment na\u00efve)', 'Or', '2. Receiving Abi/Enza/Apa for mCRPC AND responding or stable', '(PSA values must be stable or declining after at least 4 weeks since', 'starting Abi/Enza/Apa for mCRPC)', 'Or', '3. Patients with PSA progression while on Abi/Enza/Apa are eligible', 'as long as they are asymptomatic AND there is no intent on starting', 'chemotherapy within 6 months', 'Or', '4. Patients treated with Docetaxel as first line therapy for mCRPC who', 'are asymptomatic without ANY evidence of progression', 'Or', '5. Patients may have progressed following Docetaxel first line and are', 'now receiving treatment with Abi/Enza/Apa. These patients must', 'absolutely be responding or stable (PSA values must be stable or', 'declining after starting Abi/Enza/Apa treatment) and have an', 'expected life expectancy of more than 1 year.', '>4 weeks since last major surgery and fully recovered.', 'No known contraindications to high intensity exercise, including, but', 'not limited to: brain metastases; current congestive heart failure', '(New York Heart Association Class II, III or IV); serious or non-', 'healing wound, ulcer, or bone fracture; spinal cord compromise or', 'instrumentation due to metastatic disease; peripheral neuropathy', 'INTERVAL Protocol Version 4.0, 19 April 2018', '3']\n\n###\n\n", "completion": "END"}